The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Soft Tissue Sarcomas

Recruiting now

Conditions studied: Advanced Soft Tissue Sarcomas

In brief

This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for advanced soft tissue sarcomas.

Key facts

Study ID

NCT06644287

Run by

Ruijin Hospital

People needed

40

Starts

2024-10-15

Expected to finish

2027-07-31

Last updated by the study team

2024-12-13

Who can join

Age: 6 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pathological and clinical diagnosis of advanced soft tissue sarcomas, pathological types include: fibrosarcoma, liposarcoma, undifferentiated pleomorphic sarcoma, epithelioid sarcoma, rhabdomyosarcoma, synovial sarcoma, alveolar soft-part sarcoma, leiomyosarcoma, clear cell sarcoma, malignant schwannoma, angiosarcoma.
• Consider immunotherapy or combined immunotherapy based on clinical judgement.
• Signed and dated informed consent form.
• Commitment to comply with research procedures and co-operation in the implementation of the full research process.
• Aged 6-80 years old.

You may not qualify if…

• Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc.
• Intestinal perforation, complete intestinal obstruction
• Pregnant women and women who may be pregnant, women who are breastfeeding.
• Non-compliant person

Where it is running

• Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.